NOTICE TO DISREGARD -- CDx Diagnostics
May 04, 2021 11:13 ET
|
CDx Diagnostics
SUFFERN, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- We are advised by CDx Diagnostics that journalists and other readers should disregard the news release, “CDx Diagnostics Contracts with Wellmark Blue...
WATS3D Receives Medically Necessary Designation from Blue Cross Blue Shield of Kansas City
March 09, 2021 11:00 ET
|
CDx Diagnostics
SUFFERN, N.Y., March 09, 2021 (GLOBE NEWSWIRE) -- WATS3D, a diagnostic platform used by physicians to detect Barrett’s esophagus (BE), pre-cancer and cancerous cells in the esophagus, has received a...
WATS3D Now Considered Medically Necessary by BlueCross BlueShield of South Carolina
January 26, 2021 14:00 ET
|
CDx Diagnostics
SUFFERN, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous and cancerous cells in the esophagus, is now...
CDx Diagnostics Awarded Federal Supply Schedule Contract
December 15, 2020 11:30 ET
|
CDx Diagnostics
Veterans now have access to WATS3D life-saving technology in the VA and community settings SUFFERN, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics has been awarded GSA Contract...
Study Confirms WATS3D as Cost-Effective Adjunct to Seattle Protocol
August 25, 2020 13:00 ET
|
CDx Diagnostics
The addition of WATS3D to the screening process for BE resulted in approximately 3 fewer cancers and 3 fewer cancer deaths per 1,000 people screened SUFFERN, N.Y., Aug. 25, 2020 (GLOBE NEWSWIRE) --...
CDx Diagnostics Announces Contract with Hawaii Medical Services Association
August 11, 2020 14:30 ET
|
CDx Diagnostics
WATS3D diagnostic platform for screening and surveillance ofBarrett’s esophagus now available to 800,000 members SUFFERN, N.Y., Aug. 11, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics, Inc. is now...
SAGES TAVAC Analysis Indicates WATS3D is a Safe and Effective Diagnostic Technique for Barrett’s Esophagus
June 16, 2020 13:00 ET
|
CDx Diagnostics
SUFFERN, N.Y., June 16, 2020 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform used to identify precancerous cells in the esophagus, has been deemed as a safe and effective adjunctive to...
CDx Diagnostics Announces Contract with Blue Cross Blue Shield of Massachusetts for WATS3D Biopsy
April 02, 2020 08:00 ET
|
CDx Diagnostics
- Newly issued coverage statement on diagnostic platform for screening and surveillance of Barrett’s esophagus - SUFFERN, N.Y., April 02, 2020 (GLOBE NEWSWIRE) -- Effective Jan. 21, 2020 – CDx...
American Society for Gastrointestinal Endoscopy Includes WATS3D in Its New Practice Guideline for the Screening and Surveillance of Barrett’s Esophagus
September 04, 2019 09:00 ET
|
CDx Diagnostics
SUFFERN, N.Y., Sept. 04, 2019 (GLOBE NEWSWIRE) -- CDx Diagnostics, developer of the WATS3D diagnostic platform for the screening and surveillance of Barrett’s esophagus (BE), a known precursor to...
New Data Presented at DDW 2019 Demonstrate That WATS3D Provides Clinical Benefit in Detecting Residual/Recurrent Intestinal Metaplasia in Post-Barrett’s Esophagus Ablation Patients
May 18, 2019 12:30 ET
|
CDx Diagnostics
- Study shows that the addition of WATS3D increased the detection of residual/recurrent intestinal metaplasia by 79% and associated dysplasia by 224% - SUFFERN, N.Y., May 18, 2019 (GLOBE NEWSWIRE)...